CVAC$5.3455
Chart
Performance
Key Stats
AI CVAC Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyCureVac N.V. shows potential for growth driven by its mRNA technology in vaccines and oncology. While current financial performance and valuation metrics suggest a cautious outlook, positive momentum in its clinical pipeline and the broader biopharmaceutical sector contribute to a favorable long-term view.
Thematic
CureVac is positioned within the high-growth mRNA therapeutics and vaccine market, with significant potential in oncology and infectious diseases. The company's focus on innovative mRNA technology aligns with major healthcare trends, but competition and regulatory hurdles are present.
Fundamental
CureVac's financial health shows mixed signals. While recent financial results indicate a transition with potential for revenue growth, the company has historically reported significant net losses. Its balance sheet remains robust with substantial cash reserves, but profitability needs to be established.
Technical
The stock is trading within its 52-week range, showing some recent upward momentum. While technical indicators suggest potential for further upside, overbought conditions on shorter timeframes might indicate a need for consolidation.
| Factor | Score |
|---|---|
| mRNA Technology Advancement | 85 |
| Oncology & Vaccine Markets | 80 |
| Competitive Landscape | 60 |
| Regulatory Environment (Biotech) | 70 |
| Partnerships and Collaborations | 80 |
| Factor | Score |
|---|---|
| Valuation | 45 |
| Profitability | 40 |
| Growth | 30 |
| Balance Sheet Health | 85 |
| Cash Flow | 35 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 70 |
| Support & Resistance | 70 |
| Trading Volume | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Earnings Surprises
The company has reported positive earnings surprises in 3 out of the last 4 quarters, indicating consistent performance exceeding analyst expectations.
Strong Cash Position
The company holds $481.75M in cash and cash equivalents, which is more than enough to cover its current liabilities of $72.35M, indicating excellent short-term financial stability.
Bearish Points (7)
Inconsistent Earnings Growth
The company has experienced negative EPS in the last two reported quarters, indicating challenges in generating consistent profits.
High Price-to-Sales Ratio
The trailing Price-to-Sales ratio of 2.4 is above the industry average, potentially indicating that the stock is overvalued relative to its revenue.
Calendar
August 2025
13
Next Earnings Date
H: $-0.15
A: $-0.18
L: $-0.22
H: 12.80M
A: 3.34M
0Profile
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Seasonals
Price Target
5.40 USD
The 39 analysts offering 1 year price forecasts for CVAC have a max estimate of 5.54 and a min estimate of 5.07.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Leading direct competitor in mRNA vaccine and therapeutic development, a core technology area for CureVac.
Weight: 95
Direct competitor and co-developer of a leading mRNA COVID-19 vaccine with Pfizer, strongly focused on mRNA technology.
Weight: 90
Key partner in mRNA vaccine development (with BioNTech) and a major pharmaceutical company with a broad vaccine and therapeutic portfolio.
Weight: 88
Direct competitor focused on developing self-amplifying mRNA-based therapeutics and vaccines, a closely related technology.